公开(公告)号：EP2866817A4

公开(公告)日：2016-04-20

申请号：EP13813082

申请日：2013-07-03

申请人： OMEROS CORP

发明人： CICCOCIOPPO ROBERTO

IPC分类号： A61K36/19 ,  A61K31/202 ,  A61K31/365 ,  A61K36/185 ,  A61K36/234 ,  A61K36/40 ,  A61K36/48 ,  A61K36/738 ,  A61K36/8884 ,  A61K36/8888 ,  A61K45/06

CPC分类号： A61K36/19 ,  A61K31/045 ,  A61K31/12 ,  A61K31/192 ,  A61K31/202 ,  A61K31/352 ,  A61K31/365 ,  A61K36/185 ,  A61K36/234 ,  A61K36/40 ,  A61K36/48 ,  A61K36/738 ,  A61K36/8884 ,  A61K36/8888 ,  A61K45/06 ,  A61K2300/00

摘要： Methods and compositions for the treatment or prevention of addictions and impulse control disorders using Andrographis paniculata, active substances contained therein and extracts thereof, alone or in combination with other therapeutic agents. The methods and compositions of the invention are useful in the treatment or prevention of addiction to substances, including alcohol, nicotine, marijuana, opioid agonists cocaine, and amphetamines, as well as impulse control disorders, including pathological gambling and pathological overeating.

摘要翻译： 方法和组合物用于治疗或预防使用穿心莲成瘾和脉冲控制障碍的，活性物质其中所含及其提取物，单独或与其它治疗剂组合。 本发明的方法和组合物是在成瘾的物质，包括酒精，尼古丁，大麻的治疗或预防是有用的，阿片受体激动剂可卡因，安非他明和，以及​​冲动控制障碍，包括病理性赌博和病理暴饮暴食。

公开(公告)号：EP2833907A4

公开(公告)日：2016-03-16

申请号：EP13798222

申请日：2013-04-05

申请人： OMEROS CORP ,  UNIV LEICESTER

发明人： SCHWAEBLE HANS-WILHELM ,  DEMOPULOS GREGORY A

IPC分类号： A61K39/00 ,  C07K16/40

CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

摘要翻译： 在一个方面，本发明提供方法和组合物用于抑制在从阵发性睡眠性血红蛋白尿症的受试者MASP-3依赖性补体活化通过给予受试者的组合物，其包括MASP-3抑制剂的量的有效抑制量 MASP-3依赖性补体活化。 在另一个方面，本发明提供了通过给受试者施用一种组合物，其包括MASP-1抑制剂中的至少一个和/或量的增加红血细胞在从阵发性睡眠性血红蛋白尿症的受治疗者的存活的方法和组合物 一个有效MASP-3抑制剂，以增加红血细胞的存活。 在一些实施方案中，受试者施用MASP-2抑制剂和MASP-1抑制剂，MASP-2抑制剂和施用MASP-3抑制剂，MASP-3抑制剂和MASP-1抑制剂 或MASP-1抑制剂，MASP-2抑制剂和MASP-3抑制剂。

公开(公告)号：EP2911511A4

公开(公告)日：2015-12-16

申请号：EP13848382

申请日：2013-10-23

申请人： OMEROS CORP

发明人： DEMOPULOS GREGORY A ,  SHEN HUI-RONG ,  TEDFORD CLARK E

IPC分类号： A61K31/137 ,  A61K9/00 ,  A61K31/138 ,  A61K31/407 ,  A61P27/08

CPC分类号： A61K31/407 ,  A61K9/0048 ,  A61K31/137 ,  A61K31/138 ,  A61K2300/00

摘要： The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

摘要翻译： 本发明涉及用于注射的苯肾上腺素和酮咯酸的稳定的防腐剂和抗氧化剂的液体制剂。

公开(公告)号：EP2427193A4

公开(公告)日：2013-04-03

申请号：EP10772372

申请日：2010-05-03

申请人： OMEROS CORP

发明人： BERGMANN JOHN E ,  CUTSHALL NEIL S ,  DEMOPULOS GREGORY A ,  FLORIO VINCENT A ,  GAITANARIS GEORGE ,  GRAY PATRICK ,  HOHMANN JOHN ,  ONRUST RENE ,  ZENG HONGKUI

IPC分类号： A61K31/50 ,  A61K31/137 ,  A61K31/195 ,  A61K31/38 ,  A61K31/415 ,  A61K31/425 ,  A61K31/433 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  A61P25/14 ,  C07D471/04

CPC分类号： A61K31/551 ,  A61K31/00 ,  A61K31/085 ,  A61K31/122 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/198 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4162 ,  A61K31/425 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/527 ,  A61K31/542 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

摘要： A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

公开(公告)号：EP1881821A4

公开(公告)日：2012-08-29

申请号：EP06748426

申请日：2006-03-17

申请人： OMEROS CORP

发明人： DEMOPULOS GREGORY A ,  HERZ JEFFREY M ,  GOMBOTZ WAYNE R ,  SHEN HUI-RONG

IPC分类号： A61K9/22 ,  A61K45/06

CPC分类号： A61K31/4422 ,  A61K9/0034 ,  A61K9/08 ,  A61K31/00 ,  A61K31/192 ,  A61K31/21 ,  A61K31/40 ,  A61K31/44 ,  A61K31/455 ,  A61L31/16 ,  A61L2300/402 ,  A61L2300/41 ,  A61L2300/432 ,  A61K2300/00

摘要： Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

公开(公告)号：EP2007425A4

公开(公告)日：2010-07-07

申请号：EP07759500

申请日：2007-03-27

申请人： UNIV LEICESTER ,  OMEROS CORP

发明人： SCHWAEBLE HANS-WILHELM ,  STOVER CORDULA MARGARET ,  TEDFORD CLARK E ,  PARENT JAMES B ,  FUJITA TEIZO

IPC分类号： A61K39/395 ,  A01K67/027 ,  C07K14/47 ,  C07K16/40

CPC分类号： C07K16/40 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0375 ,  A61K39/395 ,  A61K49/0008 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/6408 ,  C12N9/6424 ,  C12Y304/21104 ,  Y10S514/912

公开(公告)号：EP2386316B1

公开(公告)日：2018-02-28

申请号：EP10183216

申请日：2005-06-09

申请人： OMEROS CORP ,  UNIV LEICESTER

发明人： SCHWAEBLE HANS-WILHELM ,  STOVER CORDULA M ,  TEDFORD CLARK E ,  PARENT JAMES B ,  FUJITA TEIZO

IPC分类号： A61K39/395 ,  A61K31/00 ,  A61K38/02 ,  A61P9/00 ,  A61P21/00 ,  A61P37/00 ,  C07K16/40

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K2039/505 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/55 ,  C12N9/6424

摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C I q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.

公开(公告)号：EP2968546A4

公开(公告)日：2016-11-02

申请号：EP14764165

申请日：2014-03-14

申请人： OMEROS CORP

发明人： CUMMINGS W JASON ,  GRAY PATRICK ,  TJOELKER LARRY W ,  YABUKI MUNEHISA

IPC分类号： A61K39/395 ,  C07K14/81 ,  C07K16/40

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K14/811 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/23 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/30

公开(公告)号：EP2544679A4

公开(公告)日：2014-05-14

申请号：EP11754087

申请日：2011-03-10

申请人： OMEROS CORP

发明人： CUTSHALL NEIL S ,  GAGE JENNIFER LYNN ,  WHEELER THOMAS NEIL ,  LITTLE THOMAS L

IPC分类号： A61K31/33

CPC分类号： C07D307/46 ,  A61K31/341 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/433 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C07D231/12 ,  C07D285/08 ,  C07D285/12 ,  C07D307/34 ,  C07D307/40 ,  C07D401/04 ,  C07D405/10 ,  C07D407/10 ,  C07D413/10 ,  C07D417/10

摘要： Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

公开(公告)号：EP2640395A4

公开(公告)日：2014-01-22

申请号：EP11840549

申请日：2011-11-07

申请人： OMEROS CORP

发明人： DEMOPULOS GREGORY A ,  GAITANARIS GEORGE A

IPC分类号： A61K31/519 ,  A61P25/30

CPC分类号： A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/197 ,  A61K31/337 ,  A61K31/357 ,  A61K31/381 ,  A61K31/385 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/454 ,  A61K31/485 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K2300/00

摘要： This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

摘要翻译： 本发明涉及治疗用磷酸二酯酶7（PDE7）抑制剂，单独或与其它治疗剂组合成瘾和初级冲动控制障碍。